

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/033334-2022>

Tender

## **(NU/1824) The Provision of Clinical Research Support & Central Laboratory Services for the ADVANCE Study**

Newcastle University

F02: Contract notice

Notice identifier: 2022/S 000-033334

Procurement identifier (OCID): ocds-h6vhtk-0387f3

Published 24 November 2022, 10:36am

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

Newcastle University

Newcastle University, Procurement Services, Kingsgate

Newcastle

NE1 7RU

#### **Contact**

Dr Emma Barksby

#### **Email**

[emma.barksby@ncl.ac.uk](mailto:emma.barksby@ncl.ac.uk)

#### **Telephone**

+44 1912086298

#### **Country**

United Kingdom

**Region code**

UKC22 - Tyneside

**Internet address(es)**

Main address

<https://www.ncl.ac.uk>

Buyer's address

<https://www.ncl.ac.uk>

**I.3) Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://procontract.due-north.com/>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://procontract.due-north.com/>

**I.4) Type of the contracting authority**

Body governed by public law

**I.5) Main activity**

Education

---

## **Section II: Object**

### **II.1) Scope of the procurement**

#### **II.1.1) Title**

(NU/1824) The Provision of Clinical Research Support & Central Laboratory Services for the ADVANCE Study

Reference number

DN644540

#### **II.1.2) Main CPV code**

- 73110000 - Research services

#### **II.1.3) Type of contract**

Services

#### **II.1.4) Short description**

The Newcastle University Translational and Clinical Research Institute is one of three research institutes established in 2019 following a restructure within the Faculty of Medical Sciences. Its members map across the biomedical research landscape. A number of major research projects are led from within the Institute including the “NASH Disease Translational Accelerator” (NASH-DTA) project. This project funded brings together clinicians and scientists from prominent academic centres across Europe and industrial partners to conduct research into advanced liver disease/cirrhosis caused by non-alcoholic fatty liver disease (NAFLD). Their common goals are developing, validating and qualifying better biomarkers for NAFLD. Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, NAFLD is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. Biomarkers under investigation in the project include genes that contribute to NAFLD progression.

The purpose of this tender process is to engage a supplier to provide clinical research support, central laboratory services and to oversee biological sample transfers and provide centralised laboratory processing of biological samples collected during the course of the study.

#### **II.1.5) Estimated total value**

Value excluding VAT: £2,200,000

### **II.1.6) Information about lots**

This contract is divided into lots: No

## **II.2) Description**

### **II.2.2) Additional CPV code(s)**

- 73111000 - Research laboratory services

### **II.2.3) Place of performance**

NUTS codes

- UKC22 - Tyneside

### **II.2.4) Description of the procurement**

The Newcastle University Translational and Clinical Research Institute is one of three research institutes established in 2019 following a restructure within the Faculty of Medical Sciences. Its members map across the biomedical research landscape. A number of major research projects are led from within the Institute including the “NASH Disease Translational Accelerator” (NASH-DTA) project. This project funded brings together clinicians and scientists from prominent academic centres across Europe and industrial partners to conduct research into advanced liver disease/cirrhosis caused by non-alcoholic fatty liver disease (NAFLD). Their common goals are developing, validating and qualifying better biomarkers for NAFLD. Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, NAFLD is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. Biomarkers under investigation in the project include genes that contribute to NAFLD progression.

The purpose of this tender process is to engage a supplier to provide clinical research support, central laboratory services and to oversee biological sample transfers and provide centralised laboratory processing of biological samples collected during the course of the study.

### **II.2.5) Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

### **II.2.6) Estimated value**

Value excluding VAT: £2,200,000

## **II.2.7) Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months

60

This contract is subject to renewal

No

## **II.2.10) Information about variants**

Variants will be accepted: No

## **II.2.11) Information about options**

Options: No

## **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

---

# **Section IV. Procedure**

## **IV.1) Description**

### **IV.1.1) Type of procedure**

Open procedure

### **IV.1.3) Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

Framework agreement with a single operator

In the case of framework agreements, provide justification for any duration exceeding 4 years:

### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: No

## **IV.2) Administrative information**

### **IV.2.2) Time limit for receipt of tenders or requests to participate**

Date

5 January 2023

Local time

12:00pm

### **IV.2.4) Languages in which tenders or requests to participate may be submitted**

English

### **IV.2.7) Conditions for opening of tenders**

Date

5 January 2023

Local time

2:00pm

---

## **Section VI. Complementary information**

### **VI.1) Information about recurrence**

This is a recurrent procurement: No

### **VI.4) Procedures for review**

#### **VI.4.1) Review body**

Newcastle University

Newcastle upon Tyne

Country

United Kingdom

#### **VI.4.3) Review procedure**

Precise information on deadline(s) for review procedures

Newcastle University will incorporate a minimum 10 calendar day standstill period at the point information on the award of the contract is communicated to tenderers. This period allows unsuccessful tenderers to seek further debriefing before the contract is entered into. Applicants have 2 working days from notification of the award decision to request additional debriefing and 4 / 4 that information has to be provided a minimum of 3 working days before expiry of the standstill period. Such additional information should be requested from the address referred to in part 1.1 above. If an appeal regarding the award of a contract has not been successfully resolved, the Public Contracts Regulations 2015 provide for aggrieved parties who have been harmed or are at risk of harm by a breach of the rules to take action in the High Court (England, Wales and Northern Ireland). Any such action must be brought promptly. Where a contract has not been entered into the Court may order the setting aside of the award decision or order the authority to amend any document and may award damages. If the contract has been entered into the Court may only award damages